Immune-Related Adverse Events in PD-1 Treated Melanoma and Impact Upon Anti-Tumor Efficacy: A Real World Analysis
BackgroundAnti-PD-1 immune checkpoint inhibitor (ICI) therapy has revolutionized the treatment of melanoma by producing durable long-term responses in a subset of patients. ICI-treated patients develop unique toxicities - immune related adverse events (irAEs) – that arise from unrestrained immune ac...
Enregistré dans:
Auteurs principaux: | Melissa L. Bastacky, Hong Wang, Dylan Fortman, Zahra Rahman, Gerard P. Mascara, Timothy Brenner, Yana G. Najjar, Jason J. Luke, John M. Kirkwood, Hassane M. Zarour, Diwakar Davar |
---|---|
Format: | article |
Langue: | EN |
Publié: |
Frontiers Media S.A.
2021
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/bb1201d2dc294e4d8fa1c2c7bb33a26c |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
Dual immunological blockade in the treatment of metastatic non-small cell lung cancer: reality and perspectives
par: Denis I. Yudin, et autres
Publié: (2021) -
Metastatic melanoma with sebocyte-like melanocytes and widespread visceral involvement
par: Li-Wei Chang, et autres
Publié: (2020) -
Treatment of Advanced Metastatic Melanoma
par: Pietro Quaglino, et autres
Publié: (2021) -
Predictive Value of Baseline [18F]FDG PET/CT for Response to Systemic Therapy in Patients with Advanced Melanoma
par: Virginia Liberini, et autres
Publié: (2021) -
INFLUENCE OF ANTIBODIES AGAINST CTLA-4 AND PD-1 UPON QUANTITIES OF THEIR TARGET RECEPTORS
par: I. O. Chikileva, et autres
Publié: (2019)